Likelihood of Approval and Phase Transition Success Rate Model – Human Papillomavirus (Virus Like Particle, 9-valent) Vaccine in Human Papillomavirus Infections

Powered by

Unlock hidden opportunities in the LoA industry

$500
lgp loa report cover Likelihood of Approval and Phase Transition Success Rate Model – Human Papillomavirus (Virus Like Particle, 9-valent) Vaccine in Human Papillomavirus Infections

Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Human Papillomavirus (Virus Like Particle, 9-valent) Vaccine in Human Papillomavirus Infections report and make more profitable business decisions.

This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Human Papillomavirus (Virus Like Particle, 9-valent) Vaccine in Human Papillomavirus Infections Drug Details:

Human papillomavirus [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (9-valent) vaccine (Gardasil 9/ Silgard 9) is a non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles, formulated as suspension for intramuscular route of administration. Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by HPV types and genital warts (Condyloma acuminata) caused by specific HPV types. Gardasil 9 indicated following precancerous or dysplastic lesions caused by HPV types 6, 11,  16, 18, 31, 33, 45, 52 and 58 : cervical intraepithelial neoplasia (CIN) grade 2/3 and cervical adenocarcinoma in situ (AIS), cervical intraepithelial neoplasia (CIN) grade 1, vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3, vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3, anal  intraepithelial neoplasia (AIN) grades 1, 2, and 3, indicated in boys 9 through 15 years of age for the prevention of  the following  diseases: anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58, genital warts (condyloma acuminata) caused by HPV types 6 and 11 And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 : anal  intraepithelial neoplasia (AIN) grades 1, 2, and 3. Gardasil 9 is also indicated for use in males 16 through 26 years of age, for the prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52 and 58, precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and genital warts caused by HPV types 6 and 11. Gardasil 9 is approved to include a 2-dose regimen for individuals 9 through 14 years of age, and for the prevention of human papillomavirus (HPV) associated cancers including oropharyngeal cancer, head and neck cancers caused by vaccine-type HPV in females and males 9 through 45 years of age.The vaccine candidate is under development for the prevention human papillomavirus associated cancer including anal dysplasia, penile cancer and human papillomavirus infections. The drug candidate is administered through intramuscular route. It is a new molecular entity (NME).

Report Coverage

The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.

The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.

Quick View – Human Papillomavirus (Virus Like Particle, 9-valent) Vaccine LOA Data
Report Segments
· Drug type

· Intervention type

Drug Name
· Human Papillomavirus (Virus Like Particle, 9-valent) Vaccine
Administration Pathway
· Intramuscular
Therapeutic Areas
· Gastrointestinal| Infectious Disease| Non Malignant Disorders| Oncology| Women's Health

Key Manufacturers
· Merck & Co Inc
Drug Development Status
· Marketed

Reasons to Buy

  • Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
  • Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
  • Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
  • Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.

Scope

  • Drug Details: Drug name, Drug type, Intervention type
  • Administration Pathway
  • Therapeutic Areas
  • Key Manufacturers
  • Drug Development Status

This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
lgp loa report cover Likelihood of Approval and Phase Transition Success Rate Model – Human Papillomavirus (Virus Like Particle, 9-valent) Vaccine in Human Papillomavirus Infections
Currency USD
$500

Can be used by individual purchaser only

$1,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Likelihood of Approval and Phase Transition Success Rate Model – Human Papillomavirus (Virus Like Particle, 9-valent) Vaccine in Human Papillomavirus Infections in real time.

  • Access a live Likelihood of Approval and Phase Transition Success Rate Model – Human Papillomavirus (Virus Like Particle, 9-valent) Vaccine in Human Papillomavirus Infections dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.